Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 14/20 | 0.70 |
| ▸ | PIK3CD | O00329 | 11/20 | 0.70 |
| ▸ | ABL1 | P00519 | 10/20 | 0.70 |
| ▸ | EGFR | P00533 | 10/20 | 0.70 |
| ▸ | HCK | P08631 | 10/20 | 0.70 |
| ▸ | KDR | P35968 | 10/20 | 0.70 |
| ▸ | PIK3CA | P42336 | 10/20 | 0.70 |
| ▸ | PIK3CB | P42338 | 10/20 | 0.70 |
| ▸ | MTOR | P42345 | 10/20 | 0.70 |
| ▸ | PIK3CG | P48736 | 10/20 | 0.70 |
| ▸ | EPHB4 | P54760 | 10/20 | 0.70 |
| ▸ | PRKDC | P78527 | 10/20 | 0.70 |
| ▸ | PI4KB | Q9UBF8 | 9/20 | 0.70 |
| ▸ | ITK | Q08881 | 1/20 | 0.64 |
| ▸ | BTK | Q06187 | 4/20 | 0.57 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.55 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.55 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.55 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.55 |
| ▸ | LCK | P06239 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3603658 | 0.83 | PIK3CD (1.00) | SRCPIK3CDABL1EGFRHCK | |
| SCHEMBL21067912 | 0.83 | PIK3CD (1.00) | SRCPIK3CDABL1EGFRHCK | |
| SCHEMBL410045 | 0.82 | BTK (0.81) | SRCABL1EGFRHCKKDR | |
| SCHEMBL1497692 | 0.79 | ITK (0.65) | SRCPIK3CDABL1EGFRHCK | |
| SCHEMBL2397532 | 0.78 | SRC (0.63) | SRCPIK3CDABL1EGFRHCK | |
| SCHEMBL2397534 | 0.78 | SRC (0.63) | SRCPIK3CDABL1EGFRHCK | |
| SCHEMBL4827163 | 0.78 | SRC (0.83) | SRCPIK3CDABL1EGFRHCK | |
| SCHEMBL14706432 | 0.78 | FGFR2 (0.74) | SRCPIK3CDABL1EGFRHCK | |
| SCHEMBL1497600 | 0.78 | ITK (0.64) | SRCPIK3CDABL1EGFRHCK | |
| SCHEMBL29351053 | 0.77 | FGFR2 (0.73) | SRCPIK3CDABL1EGFRHCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542492-B2 | Ligand-directed covalent modification of protein | CELGENE CAR LLC (BM) | 2023-01-03 | — | — | US | disclosed |
| US-20170218353-A1 | Ligand-Directed Covalent Modification of Protein | CELGENE CAR LLC (BM) | 2017-08-03 | — | — | US | disclosed |
| US-20170218353-A1 | Ligand-Directed Covalent Modification of Protein | CELGENE CAR LLC (BM) | 2017-08-03 | — | — | US | disclosed |
| US-20110269244-A1 | LIGAND-DIRECTED COVALENT MODIFICATION OF PROTEIN | CELGENE CAR LLC (BM) | 2011-11-03 | — | — | US | disclosed |
| US-20110269244-A1 | LIGAND-DIRECTED COVALENT MODIFICATION OF PROTEIN | CELGENE CAR LLC (BM) | 2011-11-03 | — | — | US | disclosed |
| WO-2011082285-A1 | LIGAND-DIRECTED COVALENT MODIFICATION OF PROTEIN | AVILA THERAPEUTICS, INC. (US) | 2011-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542492-B2 | Ligand-directed covalent modification of protein | PTMS, SPR, DNPEP | SRC 316/4885PIK3CD 4347/4885ABL1 367/4885 |
| US-20110269244-A1 | LIGAND-DIRECTED COVALENT MODIFICATION OF PROTEIN | PTMS, SPR, DNPEP | SRC 316/4885PIK3CD 4347/4885ABL1 367/4885 |
| US-20170218353-A1 | Ligand-Directed Covalent Modification of Protein | PTMS, SPR, DNPEP | SRC 316/4885PIK3CD 4347/4885ABL1 367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.